Clinical Trial

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research is to test if mutations (changes in DNA) in exons (segment of DNA or RNA containing information that has the instructions for making proteins) in the KIT gene can be used to predict the body's response to standard of care treatment.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-05-05; most recent amendment 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2022-07-28
Trial Details
NCT Number NCT05366816
Lead Sponsor University of Miami
Conditions Gastrointestinal Stromal Tumors
Enrollment 48 participants
Start Date 2023-10-17
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-09